Zhao et al., 2017
"With over half of adults in Europe living with overweight or obesity, understanding who may benefit most from interventions that encourage adherence is essential to improving treatment use and subsequent health outcomes and quality of life." Despite the important findings, the authors acknowledge serval limitations of the study, including that anthropometric measures such as the exact BMI are not generally available in Danish health registries, and they could not assess individual-level income, insurance coverage, or out-of-pocket pay, which could partially affect the conclusions
and a 500 mcg level, a higher potency that can be leveraged as a loading level or applied to cases where more support is needed
[Saxenda] is the fifth first-to-market entry of a Teva generic this year and is an important addition to Teva's diverse complex generics portfolio" Ernie Richardsen, Head of US Commercial Generics at Teva, said: This is the fifth first-to-market entry of a Teva generic this year and is an important addition to Teva's diverse complex generics portfolio. Approval of the GLP-1 will see Teva compete with Novos obesity drug Wegovy (semaglutide), which it markets as Ozempic to treat diabetes, and Lillys Zepbound (tirzepatide)
Apr 26 2019;11(5)doi:10.3390/nu11050962 Boniol M, Franchi M, Bota M, et al
(2025-c)